Psychotherapists' openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment.

Meir, Priel; Taylor, Leslie; Soares, Jair C; Meyer, Thomas D

Meir, Priel; Taylor, Leslie; Soares, Jair C; Meyer, Thomas D.

Afiliación

Meir P; Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, UTHealth Science Center at Houston, Houston, TX, United States.
Taylor L; Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, UTHealth Science Center at Houston, Houston, TX, United States.
Soares JC; Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, UTHealth Science Center at Houston, Houston, TX, United States.
Meyer TD; Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, UTHealth Science Center at Houston, Houston, TX, United States. Electronic address: Thomas.D.Meyer@uth.tmc.edu.

J Affect Disord ; 323: 748-754, 2023 02 15.

Article en En | MEDLINE | ID: mdl-36535547

Asunto(s)

Alucinógenos; Psilocibina; Humanos; Psilocibina/uso terapéutico; Alucinógenos/uso terapéutico; Salud Mental; Psicoterapeutas; Psicoterapia

Palabras clave

Barriers to treatment; Mental health professionals; Psilocybin; Psilocybin-assisted therapy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psilocibina / Alucinógenos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Affect Disord Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google